🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

406 results for “The George Institute” Clear

  1. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    The George Institute

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    phase 3 small molecule active

    1 trial

  2. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  3. METHYLPREDNISOLONE , ACETYLCYSTEINE

    The George Institute

    Acute Alcoholic hepatitis

    phase 3 small molecule active

    1 trial

  4. Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  5. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  6. Metformina Uxa 850 mg comprimidos recubiertos con película EFG, El producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur, acondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo.

    The George Institute

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  7. Mirena 20 mikrogram/24 timmar intrauterint inlägg, Kyleena® 19,5 mg, intrauterint inlägg, Jaydess 13,5 mg, intrauterint inlägg

    The George Institute

    Post medical abortion contraception

    phase 3 small molecule active

    1 trial

  8. Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung

    The George Institute

    Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.

    phase 3 small molecule active

    1 trial

  9. Natriumklorid Braun 9 mg/ml spädningsvätska för parenteral användning, COLECALCIFEROL , GRAZAX 75 000 SQ-T frystorkad sublingual tablett, Alutard SQ Timotej, 10 000 SQ-E/ml, injektionsvätska, suspension

    The George Institute

    Allergisk Rinit

    phase 3 small molecule active

    1 trial

  10. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  11. OCTAGAM 10 %, Lösung zur intravenösen Infusion, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Prednisolone 5mg Tablets, Methotrexate 10 mg Tablets, Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion, INDOMETACIN CAPSULES BP 25mg, LEMTRADA 12 mg concentrate for solution for infusion, Mercaptopurine Silver Pharma 50 mg tablets, LITAK 2 mg

    The George Institute

    Langerhans Cell Histiocytosis

    phase 3 small molecule active

    1 trial

  12. OFOBA : Opioid-Free versus Opioid-Based Anaesthesia for free-flap reconstruction surgery of the breast: A phase III multicentric randomized controlled study.

    The George Institute

    Anaesthesia during free flap reconstruction surgery of the breast.

    phase 3 other active

    1 trial

  13. OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Metastatic renal cell carcinoma (mRCC)

    phase 3 small molecule active

    1 trial

  14. Placebo Rosuvastatin Calcium 20 mg tablets, ROSUVASTATIN CALCIUM

    The George Institute

    Venous thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis

    phase 3 small molecule active

    1 trial

  15. Placebo capsules for Doxycycline 200 mg (Empty Hpmc capsule, vcaps plus, swedish orange filled with microcrystalline cellulose), Doxycycline EG 100 mg tabletten

    The George Institute

    bacterial sexually transmitted infections

    phase 3 small molecule active

    1 trial

  16. Placebo for Clarithomycin film-coated tablets (500mg), KLARICID® 500 mg επικαλυμμένα με λεπτό υμένιο δισκία

    The George Institute

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  17. Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  18. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  19. Placebo, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG

    The George Institute

    Fibrosis liber, chronic liver disease, alcoholic liver disease

    phase 3 small molecule active

    1 trial

  20. Pravastatina Kern Pharma 40 mg comprimidos EFG, Placebo Pravastatina

    The George Institute

    intrauterine growth restriction, preeclampsia

    phase 3 small molecule active

    1 trial

  21. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  22. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies infection/prophylaxis

    phase 3 small molecule active

    1 trial

  23. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

  24. Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources